This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Bluming AZ. 2022 Hormone replacement therapy after breast cancer. The Cancer Journal: in press.
Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?) a randomized comparison: trial stopped. Lancet 363:453–455
Holmberg L, Iverson OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482
Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299
von Schoultz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97(7):533–5
Fahlén M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow-up of the Stockholm randomized trial. Eur J Cancer 49:52–59
Palshof T, Mouridsen HT, Daehnfeldt JL (1980) Adjuvant endocrine therapy of breast cancer-a controlled clinical trial of oestrogen and anti-oestrogen: Preliminary results of the Copenhagen breast cancer trials. Eur J Cancer 71:183–187 (Also in Recent Results Cancer Research 1980; 71:185-9)
Palshof T, Carstensen B, Mouridsen HT et al (1985) Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Rev Endocrine Related Cancer 17:43–50
Eden JA, Bush T, Nand S, Wren BG (1995) A case -controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer. Menopause 2:67–72
Disaia PJ, Brewster WR, Ziogas A et al (2000) Breast cancer survival and hormone replacement therapy. A cohort analysis. Am J Clin Oncol 23:541–5
Poggio F, Del Mastro L, Bruzzone M et al (2021) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-021-06436-9
Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN et al (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year prospective study. Cancer 95:1817–1826
Vassilopoulou-Sellin R, Klein MJ (1996) Estrogen replacement therapy after therapy for localized breast carcinoma: Patient responses and opinions. Cancer 78:1043–1048
Kenemans P, Bundred NJ, Foidart J-M et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. Lancet Oncol 10:135–146
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bluming, A.Z. Safety of systemic hormone replacement therapy in breast cancer survivors. Breast Cancer Res Treat 191, 685–686 (2022). https://doi.org/10.1007/s10549-021-06479-y